Key Binding and Susceptibility of NS3/4A Serine Protease Inhibitors against Hepatitis C Virus
暂无分享,去创建一个
Thanyada Rungrotmongkol | Supot Hannongbua | Arthitaya Meeprasert | T. Rungrotmongkol | S. Hannongbua | A. Meeprasert
[1] McKenzie Ferguson,et al. Current Therapies for Chronic Hepatitis C , 2011, Pharmacotherapy.
[2] Thanyada Rungrotmongkol,et al. Molecular Dynamic Behavior and Binding Affinity of Flavonoid Analogues to the Cyclin Dependent Kinase 6/cyclin D Complex , 2012, J. Chem. Inf. Model..
[3] Peter W. White,et al. Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease , 2010, Antimicrobial Agents and Chemotherapy.
[4] H. Parge,et al. The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site , 1996, Cell.
[5] R. De Francesco,et al. Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. , 2000, Current topics in microbiology and immunology.
[6] Nopporn Kaiyawet,et al. Molecular insight into the specific binding of ADP-ribose to the nsP3 macro domains of chikungunya and Venezuelan equine encephalitis viruses: molecular dynamics simulations and free energy calculations. , 2010, Journal of molecular graphics & modelling.
[7] William McDowell,et al. Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates. , 2010, Bioorganic & medicinal chemistry letters.
[8] Tingjun Hou,et al. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..
[9] Seng-Lai Tan,et al. Hepatitis C viruses : genomes and molecular biology , 2006 .
[10] Weiwei Xue,et al. Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis , 2014, J. Chem. Inf. Model..
[11] Hong Cao,et al. The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors , 2012, PLoS pathogens.
[12] L. Vrang,et al. In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435 , 2010, Antimicrobial Agents and Chemotherapy.
[13] Huanxiang Liu,et al. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. , 2012, Antiviral research.
[14] William L. Jorgensen,et al. Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..
[15] S. Pricl,et al. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus. , 2004, Journal of molecular graphics & modelling.
[16] Tan Sl. HCV NS3-4A Serine Protease -- Hepatitis C Viruses: Genomes and Molecular Biology , 2006 .
[17] A. Hallberg,et al. Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. , 2001, Bioorganic & medicinal chemistry letters.
[18] G. Kukolj,et al. In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335 , 2011, Antimicrobial Agents and Chemotherapy.
[19] Zhuyan Guo,et al. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. , 2007, Journal of medicinal chemistry.
[20] T. Rungrotmongkol,et al. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1. , 2012, Journal of molecular graphics & modelling.
[21] A. Molla,et al. Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System , 2007, Antimicrobial Agents and Chemotherapy.
[22] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[23] P. Kollman,et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.
[24] Chao Lin,et al. HCV NS3-4A Serine Protease , 2006 .
[25] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[26] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[27] Huanxiang Liu,et al. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis. , 2012, Molecular bioSystems.
[28] Vladimı́r Frecera,et al. Structure-based design of inhibitors of NS 3 serine protease of hepatitis C virus , 2003 .
[29] S. Lemon,et al. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Harper,et al. The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease. , 2004, Journal of medicinal chemistry.
[31] Wei Zhang,et al. A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..
[32] Kai Lin. Development of novel antiviral therapies for hepatitis C virus , 2010, Virologica Sinica.
[33] Wei Zhang,et al. Prediction of binding for a kind of non-peptic HCV NS3 serine protease inhibitors from plants by molecular docking and MM-PBSA method. , 2007, Bioorganic & medicinal chemistry.
[34] Nopporn Kaiyawet,et al. Effect of Halogen Substitutions on dUMP to Stability of Thymidylate Synthase/dUMP/mTHF Ternary Complex Using Molecular Dynamics Simulation , 2013, J. Chem. Inf. Model..
[35] Jan H. Jensen,et al. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.
[36] M. Rossmann,et al. Refined structure of Sindbis virus core protein and comparison with other chymotrypsin-like serine proteinase structures. , 1993, Journal of molecular biology.
[37] M. Murcko,et al. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics. , 2007, Bioorganic & medicinal chemistry letters.
[38] T. Darden,et al. The effect of long‐range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods , 1993 .
[39] C. Schiffer,et al. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding , 2010, Proceedings of the National Academy of Sciences.
[40] S. Locarnini,et al. Hepatitis C virus resistance to protease inhibitors. , 2011, Journal of hepatology.
[41] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[42] F. Zoulim,et al. Current and emerging therapeutic approaches to hepatitis C infection , 2003, Expert review of anti-infective therapy.
[43] T. Lin,et al. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques. , 2008, Journal of molecular graphics & modelling.
[44] O. Hucke,et al. Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335* , 2011, The Journal of Biological Chemistry.
[45] Dylan P. Hartley,et al. Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227) , 2008, Antimicrobial Agents and Chemotherapy.
[46] T. Mahmood,et al. An overview about hepatitis C: A devastating virus , 2010, Critical reviews in microbiology.
[47] Holger Gohlke,et al. Converging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf , 2004, J. Comput. Chem..
[48] Charles M. Rice,et al. Unravelling hepatitis C virus replication from genome to function , 2005, Nature.
[49] C. Taft,et al. Computer-Assisted Analysis of the Interactions of Macrocyclic Inhibitors with wild Type and Mutant D168A Hepatitis C Virus NS3 Serine Protease , 2006 .
[50] R. De Francesco,et al. Multiple Enzymatic Activities Associated with Recombinant NS3 Protein of Hepatitis C Virus , 1998, Journal of Virology.
[51] B. Walker,et al. Hepatitis C virus infection. , 2001, The New England journal of medicine.
[52] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..